US STOCK
ALNY Stock Analysis
US stocks · market data · technical indicators
Alnylam Pharmaceuticals, Inc.
ALNYUS stocks9/12 上午12:34 updated
$253.26
+5.75+2.32%
Open
$248.05
High
$253.43
Low
$246.01
Volume
45.94萬
ALNY price history
+14.49%Open
221.20
Latest
253.26
High
267.40
Low
221.20
Average
241.51
Advertisement
AI Composite Technical Analysis
BetaFormula: fundamentals (40%) + technical indicators (30%) + market sentiment (30%)
AI Score90
Score range 0–100; a higher score indicates a stronger buy signal
Market Status
BuyCurrent Price$253.26
Target Price$354.564
Change %+2.32%
Institutional
Net Buying
Foreign Ownership
Reducing
Market Heat
Positive
Fundamentals (US)
P/E Ratio
44.11x
ROE
96.56%
P/B Ratio
25.01x
Dividend Yield
--
Market Insight
The composite score points to a strong buy signal (90/100), with several technical and fundamental indicators in positive territory. Return on equity of 96.56% indicates solid profitability. The target price implies roughly 40.00% upside.
This analysis is for reference only and does not constitute investment advice. Investing carries risk; educational content only.
Financial snapshot
ALNY - Alnylam Pharmaceuticals, Inc.
EPS
5.74USD
Forward EPS
12.47USD
P/E
44.11x
Forward P/E
20.30x
P/B
25.01x
ROE
96.56%
ROA
12.34%
Operating margin
17.93%
Profit margin
16.13%
Revenue growth
66.90%
Earnings growth
--
Dividend yield
--
Financial statements
| 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | |
|---|---|---|---|---|---|
| Revenue | $1.29B | $1.17B | $1.10B | $1.25B | $773.69M |
| Gross profit | $992.50M | $956.05M | $829.31M | $1.05B | $630.74M |
| Operating income | $231.44M | $268.64M | $131.72M | $367.98M | -$16.20M |
| Net income | $164.49M | $205.99M | $186.42M | $251.08M | -$72.23M |
| Basic EPS | 1.23 | 1.55 | 0.84 | 1.91 | -0.55 |
| Diluted EPS | 1.21 | 1.51 | 0.82 | 1.84 | -0.55 |
Estimates vs actuals
Next earnings
2026-10-29
EPS estimate
2.32
Revenue estimate
$1.44B
Last surprise
-14.21%
| Date | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-10-29 | 2.32 | Not reported | — |
| 2026-07-30 | 2.14 | 1.84 | -14.21% |
| 2026-04-30 | 1.47 | 1.99 | +35.30% |
| 2026-02-12 | 1.50 | 1.25 | -16.50% |
| 2025-10-30 | 1.75 | 2.90 | +66.12% |
| 2025-07-31 | 0.15 | 0.32 | +119.58% |
| 2025-05-01 | -0.37 | -0.01 | +97.29% |
| 2025-02-13 | -0.14 | 0.06 | +142.52% |
| 2024-10-31 | -0.39 | -0.50 | -26.71% |
| 2024-08-01 | -0.69 | 0.56 | +181.07% |
| 2024-05-02 | -0.63 | -0.16 | +74.50% |
| 2024-02-15 | -0.77 | -0.77 | -0.20% |
Institutional holders
| Institution | Quarter | Value held | Portfolio weight |
|---|---|---|---|
| VANGUARD GROUP INC | 2025-12-31 | $5.4B | 0.08% |
| BlackRock Inc. | 2024-06-30 | $2.3B | 0.05% |
| STATE STREET CORP | 2026-06-30 | $1.1B | 0.03% |
| TWO SIGMA INVESTMENTS, LP | 2026-06-30 | $564.7M | 0.41% |
| CITADEL ADVISORS LLC | 2026-06-30 | $57.5M | 0.01% |
| Bridgewater Associates, LP | 2026-06-30 | $30M | 0.12% |
13F quarterly filings. Reporting periods differ by institution; value and weight reflect each institution's own latest quarter.
Analyst ratings
Mean target
$371.35
Target range
$256.00 – $536.00
Implied upside
46.66%
Strong buy
6
Buy
16
Hold
7
Sell
0
Strong sell
0
Advertisement